The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
CDC 2024 data shows US obesity rates dipping for the first time in decades, thanks to Ozempic and GLP-1 drugs. Originally a diabetes treatment, these medications mimic GLP-1 hormones for dramatic weight loss. Learn the serendipitous science behind them and their broader implications.
GLP-1 drugs are revolutionizing more than just waistlines, with nationwide usage doubling rapidly. These medications mimic the gut hormone glucagon-like peptide to signal fullness to the brain and slow gut motility. However, they often trigger GI side effects like nausea and vomiting, especially during dose changes.
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
A retrospective study of 250 adults found most safely used GLP-1 receptor agonists and dermatologic biologics together for 19 months. Only 19-39% of discontinuations linked to side effects, matching known individual drug profiles. Clinicians gain reassurance for patients with metabolic and immunologic needs.
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
Lupin has signed a licensing and supply agreement with Galenicum for injectable Semaglutide in 23 countries. Galenicum handles development and manufacturing, while Lupin manages approvals and commercialization. This boosts access to the GLP-1 drug for diabetes and obesity treatment.
A woman called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain hospitalized her with pancreatitis linked to the drug. Now facing lifelong risks, she warns others to monitor symptoms closely.
Alisha Trafford called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain led to hospitalizations for pancreatitis and pancreatic necrosis, linked by doctors to the drug. She warns others to monitor symptoms closely.
GLP-1 receptor agonists excel in weight management and glucose control, but their effects on women's reproductive health demand attention. These drugs can restore ovulation in obese women with insulin resistance, yet they risk unplanned pregnancies and are unsafe during gestation. Consult experts before use.
